Qiagen N.V. Logo

Qiagen N.V.

Provider of technologies transforming biological materials into molecular insights.

QIA | F

Overview

Corporate Details

ISIN(s):
DE000A286LP0 (+5 more)
LEI:
54930036WK3GMCN17Z57
Country:
Netherlands
Address:
HULSTERWEG 82, 5912 PL VENLO

Description

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 00:00
Q3 statement / Q3 financial report 2025
English 896.5 KB
2025-11-04 19:02
QIAGEN N.V.: QIAGEN announces CEO transition plan
English 6.5 KB
2025-09-30 11:25
Qiagen N.V., Halfjaarlijkse financiële verslaggeving
English 268.3 KB
2025-08-28 07:57
QIAGEN N.V.: QIAGEN N.V. launches non-US offering of net share settled converti…
English 18.4 KB
2025-08-22 00:00
Half-yearly financial report 2025
English 428.1 KB
2025-05-13 00:00
Q1 statement / Q1 financial report 2025
English 693.8 KB
2025-05-07 14:35
QIAGEN N.V.: QIAGEN to propose initiation of annual cash dividend for sharehold…
English 6.8 KB
2025-04-28 16:33
Qiagen N.V., Jaarlijkse financiële verslaggeving
English 23.4 MB
2025-04-06 18:20
QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates fu…
English 7.2 KB
2025-03-31 00:00
Annual financial report 2024
English 6.2 MB
2025-02-06 06:31
QIAGEN delivers solid Q4 2024 growth ahead of outlook
English 478.9 KB
2025-01-13 18:55
QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders throug…
English 7.7 KB
2025-01-12 18:55
QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders throug…
English 7.7 KB
2024-11-07 07:30
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024…
English 421.6 KB
2024-09-03 09:01
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
English 56.8 KB

Automate Your Workflow. Get a real-time feed of all Qiagen N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Qiagen N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Qiagen N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-04-17 S. Rusckowski Non-Executive member Other 26 N/A
2023-03-14 E.R. Mardis Non-Executive member Sell 4,739 218,422.41 USD
2023-02-28 E. Pisa Non-Executive member Other 7,917 N/A
2023-02-21 R. Sackers Non-Executive member Other 51,500 N/A
2022-12-01 R. Sackers Non-Executive member Sell 30,000 1,500,000.00 USD
2022-10-31 M. Colpan Non-Executive member Other 457 N/A
2022-06-08 R. Sackers Non-Executive member Sell 32,398 1,522,706.00 USD
2022-03-31 R. Sackers Non-Executive member Other 72,944 N/A
2022-03-15 R. Sackers Non-Executive member Other 7,606 N/A
2022-03-14 E.R. Mardis Non-Executive member Sell 5,003 228,330.77 USD

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.